Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry.
Nagafuji K, Matsuo K, Teshima T, Mori S, Sakamaki H, Hidaka M, Ogawa H, Kodera Y, Kanda Y, Maruta A, Mori T, Yoshiba F, Ichinohe T, Kasai M, Takatsuka Y, Kubo K, Sao H, Atsuta Y, Suzuki R, Yoshida T, Tsuchida M, Harada M. Nagafuji K, et al. Among authors: kubo k. Int J Hematol. 2010 Jun;91(5):855-64. doi: 10.1007/s12185-010-0581-1. Epub 2010 May 14. Int J Hematol. 2010. PMID: 20464644
A single high-resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low-resolution HLA mismatch.
Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Hidaka M, Kubo K, Miyamura K, Tsudo M, Kobayashi H, Maesako Y, Eto T, Adachi S, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Fuji S, et al. Among authors: kubo k. Am J Hematol. 2015 Jul;90(7):618-23. doi: 10.1002/ajh.24028. Am J Hematol. 2015. PMID: 25850370 Free article.
High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, Akasaka T, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J, Suzuki R; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Kondo E, et al. Among authors: kubo k. Biol Blood Marrow Transplant. 2019 May;25(5):899-905. doi: 10.1016/j.bbmt.2019.01.020. Epub 2019 Jan 18. Biol Blood Marrow Transplant. 2019. PMID: 30664936 Free article.
A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors.
Yokoyama Y, Maie K, Fukuda T, Uchida N, Mukae J, Sawa M, Kubo K, Kurokawa M, Nakamae H, Ichinohe T, Atsuta Y, Chiba S. Yokoyama Y, et al. Among authors: kubo k. Bone Marrow Transplant. 2020 Sep;55(9):1726-1735. doi: 10.1038/s41409-020-0817-5. Epub 2020 Feb 10. Bone Marrow Transplant. 2020. PMID: 32042104
Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT.
Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Hidaka M, Kubo K, Miyamura K, Ohashi K, Kobayashi H, Maesako Y, Adachi S, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Fuji S, et al. Among authors: kubo k. Bone Marrow Transplant. 2014 Sep;49(9):1187-92. doi: 10.1038/bmt.2014.141. Epub 2014 Jul 7. Bone Marrow Transplant. 2014. PMID: 25000457
Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation.
Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, Amano I, Ohta T, Miyazaki Y, Kanda J, Fukuda T, Atsuta Y, Kondo E; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Sakurai M, et al. Among authors: kubo k. Bone Marrow Transplant. 2021 Jun;56(6):1462-1466. doi: 10.1038/s41409-020-01192-8. Epub 2021 Jan 29. Bone Marrow Transplant. 2021. PMID: 33514920 No abstract available.
Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.
Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T. Murata M, et al. Among authors: kubo k. Bone Marrow Transplant. 2017 Feb;52(2):252-257. doi: 10.1038/bmt.2016.247. Epub 2016 Nov 21. Bone Marrow Transplant. 2017. PMID: 27869808 Clinical Trial.
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Among authors: kubo k. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.
Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R. Wakita A, et al. Among authors: kubo k. Int J Hematol. 2012 Jul;96(1):84-93. doi: 10.1007/s12185-012-1105-y. Epub 2012 May 26. Int J Hematol. 2012. PMID: 22639053 Clinical Trial.
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T. Hosono N, et al. Among authors: kubo k. Int J Clin Oncol. 2021 Nov;26(11):2131-2141. doi: 10.1007/s10147-021-02006-7. Epub 2021 Aug 7. Int J Clin Oncol. 2021. PMID: 34363558 Free PMC article. Clinical Trial.
2,185 results